Key facts
- This page summarizes Peter Greenleaf's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2022, 15:11.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Additional SEC filing notes
Footnote F1
On March 18, 2021, the Reporting Person was granted stock based performance awards ("Performance Awards") which vests when specific performance metrics are met based on the results for the year ended December 31, 2021. It was determined that as of March 2, 2022, the Reporting Person partially met the performance criteria and received shares of common stock for no consideration.
Footnote F2
Includes 282 shares acquired by the Reporting Person under the Issuer's 2021 Employee Share Purchase Plan on December 1, 2021.
Footnote F3
Represents the number of shares sold to cover tax withholding obligations in connection with the vesting of Performance Awards.
Footnote F4
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in three (3) equal annual installments beginning March 2, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date.
Footnote F5
One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.